← BIO-RAD LABORATORIES, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $456.3m | $383.8m | $431.5m | $660.7m | $662.2m | $470.8m | $434.2m | $403.8m | $488.1m | $529.8m | |
| Short-term Investments | $383.2m | $371.2m | $413.3m | $454.0m | $328.9m | $399.1m | $1.4b | $1.2b | $1.2b | $1.0b | |
| Inventory, Net | $525.0m | $594.8m | $583.8m | $554.0m | $622.3m | $572.2m | $719.3m | $780.5m | $760.0m | $740.7m | |
| Assets, Current | $1.8b | $2.0b | $2.0b | $2.2b | $2.1b | $2.0b | $3.2b | $3.0b | $3.0b | $2.9b | |
| Property, Plant and Equipment, Net | $488.6m | $493.5m | $508.7m | $499.3m | $491.4m | $491.0m | $498.6m | $529.0m | $528.1m | $539.9m | |
| Goodwill | $477.1m | $506.1m | $219.8m | $264.1m | $291.9m | $347.3m | $406.5m | $413.6m | $410.5m | $579.8m | |
| Intangible Assets, Net (Excluding Goodwill) | $161.6m | $174.1m | $133.1m | $145.5m | $199.5m | $253.9m | $332.1m | $320.5m | $293.6m | $174.3m | |
| Operating Lease, Right-of-Use Asset | — | — | $0 | $201.9m | $202.1m | $204.8m | $181.0m | $194.7m | $160.5m | $170.0m | |
| Other Assets, Noncurrent | — | $94.9m | $70.3m | $79.6m | $86.7m | $102.7m | $94.6m | $94.8m | $101.9m | $102.7m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $372.3m | $464.8m | $392.4m | $392.7m | $419.4m | $423.5m | $494.6m | $489.0m | $452.5m | $460.6m | |
| Assets | $3.9b | $4.3b | $5.6b | $8.0b | $13.0b | $17.8b | $13.5b | $12.3b | $9.4b | $10.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | $0 | $35.4m | $36.5m | $36.4m | $36.3m | $40.4m | $41.7m | $36.1m | |
| Accounts Payable, Current | $133.1m | $135.2m | $122.5m | $107.0m | $139.5m | $141.9m | $135.0m | $144.6m | $122.3m | $129.0m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $176.0m | $175.1m | $175.9m | $153.6m | $165.5m | $131.4m | $145.7m | |
| Deferred Revenue, Current | $31.0m | $28.2m | $26.9m | $33.7m | $42.5m | $50.9m | $52.2m | $51.1m | $47.8m | $48.9m | |
| Long-term Debt, Excluding Current Maturities | $334k | $420k | $493k | $426.2m | $1.8m | $489k | $465k | $1.2b | $1.2b | $1.2b | |
| Liabilities, Current | $471.3m | $502.7m | $450.8m | $905.5m | $631.5m | $680.9m | $568.7m | $522.8m | $467.8m | $517.0m | |
| Deferred Income Tax Liabilities, Net | — | — | — | — | $2.1b | $3.1b | $1.8b | $1.5b | $818.0m | $1.1b | |
| Other Liabilities, Noncurrent | $135.3m | $183.3m | $147.8m | $160.9m | $197.0m | $182.2m | $195.9m | $195.1m | $177.2m | $199.1m | |
| Deferred Tax Liabilities, Net | $189.9m | $173.4m | $504.4m | $948.2m | $2.0b | $3.0b | $1.7b | $1.4b | $771.4m | $1.0b | |
| Liabilities | $1.3b | $1.3b | $1.6b | $2.3b | $3.1b | $4.1b | $3.9b | $3.6b | $2.8b | $3.1b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | |
| Additional Paid in Capital | $332.9m | $361.2m | $394.3m | $410.0m | $429.4m | $441.7m | $447.5m | $449.1m | $463.2m | $476.0m | |
| Retained Earnings (Accumulated Deficit) | $1.8b | $1.8b | $3.7b | $5.5b | $9.3b | $13.5b | $9.9b | $9.3b | $7.4b | $8.2b | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $417.8m | $738.8m | ($47.0m) | ($87.3m) | $282.5m | ($175.6m) | ($466.8m) | ($336.0m) | ($538.2m) | ($189.1m) | |
| Stockholders' Equity Attributable to Parent | $2.6b | $2.9b | $4.0b | $5.8b | $9.9b | $13.7b | $9.6b | $8.7b | $6.6b | $7.5b | |
| Liabilities and Equity | $3.9b | $4.3b | $5.6b | $8.0b | $13.0b | $17.8b | $13.5b | $12.3b | $9.4b | $10.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.